FLAG İDA PROTOKOLÜ

Kaynaklar:

1- Gandhi, V., E. Estey, M. J. Keating, et al. 1993. "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy." J Clin Oncol. 11(1):116-124. 

2- Parker, J. E., A. Pagliuca, A. Mijovic, et al. 1997. "Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia." Br.J.Haematol. 99(4):939-944. 

3-Virchis, A., M. Koh, P. Rankin, et al. 2004. "Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes." Br.J.Haematol. 124(1):26-32. 

4- Steinmetz, H. T., A. Schulz, P. Staib, et al. 1999. "Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML." Ann Hematol 78(9):418-425.

5- Pastore, D., G. Specchia, P. Carluccio, et al. 2003. "FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience." Ann Hematol 82(4):231-235. 

6- Martin, M. G., K. M. Augustin, G. L. Uy, et al. 2009. "Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF." Am J Hematol 84(11):733-737.